Moleculin Reports Dosing of Novel Brain Cancer Drug WP1066 in P-I trial for the treatment of Brain Tumor

 Moleculin Reports Dosing of Novel Brain Cancer Drug WP1066 in P-I trial for the treatment of Brain Tumor

Moleculin Reports Dosing of Novel Brain Cancer Drug WP1066 in P-I trial for the treatment of Brain Tumor

Shots:

  • The P-I trial is assessing WP1066 in 15 patients with relapsed brain tumor for 6 to 8mos, testing its safety and tolerability in patients at MD Anderson Cancer Centre
  • WP1066 a novel STAT3i (originated from active ingredient in propolis) has shown promising results in animal studies inhibiting tumor growth with improvement in survival
  • Mayo Clinic and Emory University is also evaluating WP1066 in pediatric brain tumor trials
  • WP1066 inhibits STAT3 (a supporter of survival and growth of tumor cells, evasion of the immune response and metastasis to distant organs) and producing anti-cancer effects in patients

Click here to read full press release/ article | Ref: Moleculin | Image: The street

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post